Replies to post #155646 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

I saw the bioavailability #'s used by KMBJN before I sent you my question via pm. I'd like to be able to pin it down a bit better before responding to some posts in the comment section of my interview with Dr Bertolino. http://seekingalpha.com/article/3988240-interview-new-cellceutix-president-dr-bertolino

Here's the KMBJN post I'd been looking at: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122883189&txt2find=ziagen|dose

I suppose I should simply ask him if he doesn't see this and elaborate.

I had started out with your post:
sox040713 Tuesday, 05/24/16 10:32:02 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122882354
10:32:02 PM
Re: BigKahuna post# 148884 Post # 148890 of 155644

Actually 200 mg of Prurisol is 2/3 of Ziagen. 350 mg of P and 300 mg of Z were dosed in Phase 1. Since there were no safety issues, my guess is that either 300 or 350 mg of P will be used in the next study.








In Reply to 'sox040713'
I got the numbers about Prurisol here.

https://clinicaltrials.gov/ct2/show/NCT02101216?term=cellceutix&rank=1

Don't forget to read KMBJN's reply because I didn't factor in its bioavailability.